December 23, 2021
CYTOCON DB and CYTOCON DB Open are updated!
CYTOCON DB is a database of human baseline concentrations of cytokines and cells measured in different tissues. CYTOCON DB Open is a version of the database designed for public use. It has the same functionality as CYTOCON DB, however, it is updated once per year.
In 2021 CYTOCON DB Open was extended with new data: 135 diseases, 109 tissues, 125 molecules, 43 cells and 22305 concentrations were introduced. For this purpose 476 articles were reviewed.
As for CYTOCON DB, its latest version 1.3.8.22 contains approximately 35000 concentrations and 1000 articles were reviewed for these purpose!
Recent update result - in unit %__T-cells_;CD8+_Blood_COVID-19 - average concentration of CD8+ T-cells was changed from 207933 to 214081 kcells/L (averaged from 135 concentrations from articles annotated to the DB)
In unit %__T-cells_;CD4+_Blood_COVID-19 - average concentration of CD4+ T-cells was changed from 345548 to 353710 kcells/L (averaged from 166 concentrations from articles annotated to the DB)
For more details, please visit: https://cytocon.insysbio.com/
To experience CYTOCON DB Open visit: https://www.cytocon-open.insysbio.com/
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | July 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
1.
14 Jul 2017 18:49
To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created
Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Jul 2017 13:50
InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.
Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2.
25 Jul 2017 17:37
InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!
Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
